Weight Loss Medications in Patients on Steroids and Mycophenolate Mofetil

Introduction to Weight Loss Medications

The American Gastroenterological Association suggests that weight loss medications can be used in patients on steroids plus mycophenolate mofetil (MMF), but requires careful selection and monitoring 1, 2

Steroids are a well-established cause of significant weight gain, making weight management a clinical concern in patients requiring chronic immunosuppression, with patients gaining substantial weight that compounds cardiovascular and metabolic risks 1, 2

The American College of Gastroenterology recommends GLP-1 receptor agonists, such as liraglutide 3.0 mg or semaglutide, as the optimal choice for patients on steroids plus MMF because they work through appetite suppression and enhanced satiety rather than GI malabsorption, avoiding exacerbating MMF's existing GI side effects, and providing modest weight loss that improves metabolic parameters 1, 4
Bupropion, alone or in combination with naltrexone, can be considered as an alternative option, working centrally through appetite suppression without significant GI effects 1, 4

Orlistat should be avoided in patients on MMF because it works through GI lipase inhibition, causing fat malabsorption and GI side effects, which could compound MMF's existing GI adverse effect profile 3, 4

Before initiating weight loss medication, assess whether weight gain is primarily steroid-induced or multifactorial, evaluate the stability of the underlying condition requiring immunosuppression, and screen for contraindications specific to each weight loss medication 1, 2, 3, 4
During treatment, monitor for worsening GI symptoms, track weight changes and metabolic parameters, and assess for drug interactions, particularly if the patient is on additional immunosuppressants like calcineurin inhibitors 3, 4

Weight loss medications typically produce modest results, with less than 5 kg weight loss at 1 year, which may not fully counteract steroid-induced weight gain, and lifestyle modifications remain essential 4
Women of childbearing age should be aware that MMF is contraindicated in pregnancy, and this should factor into the overall risk-benefit discussion 3
Patients with cirrhosis or severe liver disease should exercise caution with any additional medications, as immunosuppression already increases infection risk 3
Patients with renal impairment may require dosing adjustments for both MMF and certain weight loss medications 3